DOI: https://doi.org/10.47275/2379-6707-114
Volume 8 Issue 2
Review Article

Scholit Publishers

Journal of Pediatrics and Congenital Disorders

A Global Perspective on Impact of Chronic Kidney Disease in Children

Riya V Raju[1], Mohammed Kaif[2] and Sushma Thouti[3]*

[1]Maharajahs Institute of Medical Sciences, Andhra Pradesh, India
[2]Mohammed Kaif (Mallareddy Medical College & Hospital, Telangana, India
[3]Kakatiya Medical College, Telangana, India

Introduction

Children who have chronic kidney disease (CKD) are more likely to get sick, die, and have a lower quality of life (QOL) throughout their whole lives. The prevalence and frequency of CKD have progressively grown [1, 2]. The epidemiological landscape reveals that, globally, CKD is ranked as the sixth fastest-growing cause of mortality, afflicting around 10% of people in developed nations [3, 4]. Between 6% and 12% of the world's population, or around 850 million individuals, are thought to have CKD, and at least 2.4 million of them pass away each year [5, 6]. Worldwide, CKD is a significant public health issue, and much adult epidemiological research has been conducted (Figure 1). On the other hand, nothing is known regarding the epidemiology of CKD in children. The historical absence of a uniform definition and well-defined categorization of CKD is one potential explanation for the limited knowledge of the epidemiology of CKD in the pediatric population. Following the release, its innovative characterization was profoundly influenced; nonetheless, there has been much discourse over its failings and potential improvements [7]. Although, currently available techniques for measuring glomerular filtration in children are improving, it is still difficult to accurately measure renal function using estimated formulas, of kidney damage. Incidences of ESRD (end-stage renal disease) have remained steady overall throughout the past 30 years, which is particularly regarding the pediatric age group world [8, 9] Regarding both the maturity level population, there were about 9 children and adolescents with ESRD in 2008, with the United States having a higher median of 15.5 [10]. The most recent occurrence in France was 8.7 parts in 2015. Although these initiatives have contributed to a better knowledge of CKD and ESRD in young people, more research needs to be done to improve the outcomes for these children.

According to registry statistics from European nations, 56 - 96 children per million have CKD [11]. The true impact of CKD on children in developing countries is unknown because, with the exception of a few tertiary centres, the majority of children with early-stage CKD go undiagnosed



Figure 1: Epidemiology of CKD: an update 2022 [12].

Correspondence to: Sushma Thouti, Kakatiya Medical College, Telangana, India, E-mail: sushmathouti005@gmail.com

Citation: Raju RV, Kaif M, Thouti S (2022) A Global Perspective on Impact of Chronic Kidney Disease in Children. J Pediatr Congenit Dis, 8(2): 114. DOI: https://doi.org/10.47275/2379-6707-114

Received: August 10, 2022; **Accepted:** September 21, 2022; **Published:** September 26, 2022

and many others pass away without accessing renal replacement therapy (RRT), which is expensive and challenging to implement in children [11]. In 2018, there were 23,000 children receiving chronic dialysis, according to the RRT Registry of the International Pediatric Nephrology Association [11].

Further to that, disease will be postulated in children with massive structural deficiencies from birth rather than waiting three months for a diagnosis. The objectives of this study were to examine the general and renal-specific self-report QOL scales, determine how children perceive having comorbidities, and recommend a suitable instrument for individual departments or individual therapeutic consumption in the future. CKD is shaped by a multitude of non-modifiable risk variables, such as genetics, sex, age, age of onset, and length of diabetes. The risk of CKD was nevertheless significantly influenced by several modifiable risk factors. Due to the ability to predict mortality, medication compliance, and hospitalizations as well as the way it reflects patients' preferences in relation to physical quality and mental health, and surroundings have been seen as essential in the clinical context [13, 14]. In line with the results of the current study and in the light of the significance that the research of HRQL (health-related quality of life) has acquired as well as the effect that pediatric patients' nephropathy disease has on them, investigations have been undertaken in Central and South American and European nations with various extents of influence on the most impacted HRQL.

Young people with CKD stages 3 - 5 between the ages of 6 and 18 were sought out by a specialized pediatric nephrology unit in the United Kingdom during routine outpatient primary care practice or after an hour of stable hemodialysis. Patients participating in this research, stages 1 and 2 of CKD were not eligible because they are unlikely to have illness symptoms and unfavorable consequences (such as nausea, lack of appetite, weakness, cold and/or tiredness, disorientation, difficulty focusing, and itchy skin). CKD stage 3 is defined as a substantial reduction in glomerular filtration rate (GFR) with or without other indicators of kidney damage; stage 4 is defined as a significant decrease in GFR with or without other signs of kidney damage; and stage 5 is defined as established renal failure (Table 1). Demographic and clinical data were obtained from 28 post-dialysis CKD children and adolescents and 28 healthy, sex- and age-matched participants. The Wagnild and Young Resilience Scale, as well as the Children's QOL Inventory, were used to measure participants' psychological well-being. The Children's Depression Inventory and the Child Anxiety Disorders Self-Report were used.

From the available epidemiological studies, the majority of them are hospital-based and conducted in Europe in the past 25 years, estimate the prevalence of paediatric CKD stages 2 to 5 between 30 and 100 per million age-related population (pmarp) each year, despite the fact that inclusion criteria are variable [15]. Around 30 pmarp, or a low prevalence of CKD stages 3 to 5, were reported in Japan, however this was due to the survey's poor reporting of paediatric CKD cases under the age of 15 in 2010 [16]. On the other hand, the prevalence was higher in the UK, at around 90 pmarp, but the study was done in a hospital, so there are questions about the area covered [17]. A higher prevalence of CKD of 330 pmarp was observed in children in Kuwait, with GFR <50 ml/min/1.73 m^2 during the duration of 1996 to 2003, and also highlighting the possible role of various genetic factors [18]. Similarly, In 2008, CKD prevalence of 330 pmarp of stages 3 - 5 was observed in the Southern Israel [19]. On the contrary, around 1% of CKD stages 2 - 5 (eGFR <75 ml/min/1.73 m^2) in children go undiagnosed in China, Iran, and Turkey according to the cross-section studies [20-22]. In the Turkish and Chinese studies, the prevalence of low eGFR <60 ml/min/1.73 m^2, potentially consistent with the presence of CKD stage 3, was 0.25%. Table 2 presents the CKD/kidney failure registries and cohort studies around the world which includes pediatric population [23].

Table 1: The following stages of chronic condition.

Stage-1	chronic albuminuria and eGFR normal 90 ml/min per 1.73 m^2
Stage-2	60 to 89 ml/min per 1.73 m^2 for eGFR
Stage-3	30 to 59 ml/min per 1.73 m^2 for eGFR
Stage-4	15 to 29 ml/min per 1.73 m^2 for eGFR
Stage-5	ESRD or an eGFR of less than 15 ml/min per 1.73 m^2

Table 2: CKD/kidney failure registries and cohort studies around the world which includes pediatric population [23].

	Country	Registry	Duration	Age	Purpose
Middle East and Southeast Asia	South Korea	KNOW-Ped CKD	2011 - On goinh	<20 years	CKD
	Japan	P-CKD	2010 - On going	3 months to 15 years	CKD
	Taiwan	TAPRC study	2009 - 2012	1 - 18 years	CKD
	Taiwan	Taiwan Renal Registry	1995 - On going	<20 years	Kidney failure
	Iran	Iranian Registry	1993	<14 years	Kidney failure
Europe	United Kingdom	UK Renal Registry	2016 - On going	All ages	Kidney failure
	Spain	-	2007 - On going	<18 years	CKD
	Turkey	-	2005	<19 years	CKD
	Belgium	-	2001 - On going	<20 years	CKD
	Serbia	SPRECKID	2000 - On going	<19 years	CKD/Kidney failure
	France	REIN	1992 - On going	<2 years	Kidney failure
	Italy	ItalKid	1990 - 2000	<20 years	CKD
	Sweden	-	1986 - 1994	0.5 - 16 years	CKD
	Netherlands	LERIC	1972 - 2010	1 - 14 years	Kidney failure
South America	Brazil	HC-UFMG	1990 - 1999	2 months - 19 years	CKD
North America	United States	CKiD	2005 - On going	1 - 16 years	CKD
	United States	USRDS	1995 - On going	All ages	Kidney failure
	United States	USRDS	1978 - On going	All ages	CKD
	United States	NAPRTCS	1987 - On going	<18 years	CKD/Kidney failure
	Canada	Canadian Pediatric ESRD Database	1992 - On going	≤18 years	Kidney failure
Others	Australlia/New Zealand	ANZDATA	1963 - On going	All ages	Kidney failure

Abbreviations: KNOW-Ped CKD, KoreaN Cohort Study for Outcomes In Patients with Pediatric CKD; P–CKD, Pediatric CKD; TAPRC, Taiwan Pediatric Renal Collaborative; SPRECKID, Serbian Pediatric Registry of Chronic Kidney Disease; REIN, Renal Epidemiology and Information Network; ItalKid, Italian Pediatric Registry of Chronic Renal Insufficiency; LERIC, Late Effects of Renal Insufficiency in Children; HC–UFMG, Interdisciplinary ConservativeManagement Program of CRI at Hospital das Clínicas; CKiD, Chronic Kidney Disease in Children; USRDS, United States Renal Data System; NAPRTCS, North American Pediatric Renal Trials and Collaborative Study; ANZDATA, Australia and New Zealand Dialysis and Transplant Registry.

CKD Etiology

The etiology of CKD was classified as either congenital (such as metabolic kidney disease, cystic kidney disease, congenital nephrotic syndrome, reflux nephropathy, obstructive uropathy, or aplasia/dysplasia/hypoplasia) or acquired (such as tubulointerstitial disease, hemolytic uremic syndrome, focal segmental glomerulosclerosis, or glomerulonephritis) (Table 3 and Table 4) [23-25].

Aplaisa/Hypoplasia/Dysplasia

The kidney has failed to grow beyond its most primitive state in renal aplasia. Early regression of the ureteric bud, altered metanephric differentiation, or defects in the ability of the branching ureteric duct and the undifferentiated metanephric blastema to communicate are all possible causes of renal aplasia, which affects the ureter and basic kidney parenchyma. The most severe of the kidney and urinary tract congenital anomalies is renal aplasia [26]. Dysplasia may be present throughout a kidney or simply in its outermost regions, or the region of the kidney that developed nephrons last. The presence of primitive mesenchymal structures, such as the primitive duct, which is the hallmark of dysplasia, is what distinguishes the condition as dysplasia. Cystic dysplasia is the term used when there are cysts along with dysplasia, while multicystic dysplastic kidney is used when there are cysts across the entire kidney [27]. A reduction of nephrons is referred to as hypoplasia. In most cases, it occurs as a result of defective branching, which causes a decrease in the number of calices and infundibulia. The condition is referred to as hypodysplasia when

Table 3: Common causes of CKD in children [24].

Etiology	Percentage (%)
Aplasia/hypoplasia/dysplasia	15.8
Obstructive uropathy	15.3
Focal segmental glomerulosclerosis	11.7
Reflux nephropathy	5.2
Polycystic disease	3.0
Chronic glomerulonephritis	3.2
Medullary cystic disease	2.7
Hemolytic uremic syndrome	2.6
Prune belly	2.5
Congenital nephrotic syndrome	2.6
Familial nephritis	2.3
Cystinosis	2.1
Pyelo/interstitial nephritis	1.7

Table 4: Causes and incidence of pediatric CKD [23].

Parameter(s)	South Korea	Japan	Taiwan	Spain	Turkey	Belgium	Serbia	Italy	Sweden	USA	USA
Database	KNOW-Ped CKD	P-CKD	TAPRC study	REPIR II	-	-	SPRECKID	ItalKid	-	NAPTRACS	CKiD
Since	2011	2010	2009	2007	2005	2001	2000	1990	1986	1994	2005
Age (years)	0 - 19	0.25 - 15	0 - 18	0 - 18	0 - 18	0 - 19	0 - 18	0 - 19	0.5 - 16	0 - 20	1 - 16
CKD by eGFR (ml/min/1.73 m^2)	All	<60	All	<90	<75	<60	15 - <90	<75	<30	<75	30 - 90
Participants	437	447	757	605	282	143	239	1197	118	7037	586
Male, N (%)	299 (68)	253 (57)	397 (52)	400 (66)	159 (56)	82 (57)	-	803 (67)	72 (61)	4506 (64)	364 (62)
Undelying disease, N (%)											
CAKUT	247 (57)	284 (64)	254 (34)	356 (59)	163 (58)	84 (59)	152 (64)	733 (61)	48 (41)	3551 (50)	327 (56)
Hypo/dys	247 (57)	218 (49)	100 (13)	-	25 (9)	56 (39)	-	689 (58)	21 (18)	1220 (17)	105 (18)
Hypo/dys with VUR	-	118 (26)	-	-	-	-	-	309 (26)	-	-	-
Reflux nephropathy	-	-	94 (12)	-	52 (18)	9 (6)	-	-	-	594 (8)	87 (0)
Obstructive uropathy	-	66 (15)	60 (8)	-	73 (26)	18 (13)	-	44 (4)	27 (23)	1454 (21)	118 (20)
Hereditary disorders	28 (6)	49 (11)	89 (12)	86 (14)	46 (16)	27 (19)	32 (13)	199 (17)	31 (26)	595 (8)	46 (8)
Glomerulopathy	93 (21)	21 (5)	353 (47)	19 (3)	46 (16)	19 (13)	19 (8)	111 (9)	21 (18)	1299 (18)	111 (19)
Unknown	0 (0)	4 (1)	0 (0)	0 (0)	22 (8)	0 (0)	4 (2)	40 (3)	0 (0)	182 (3)	-
Incidence (pmarp)	NA	NA	NA	8.7	10.9	11.9	14.3	12.1	7.7	NA	NA
Prevalence (pmarp)	NA	29.8	NA	71.1	NA	NA	96.1	74.7	29.3	NA	NA

CAKUT includes aplastic kidney, hypo/dys, medullary cystic disease, multicystic-dysplastic kidney, neurogenic bladder, obstructive uropathy, reflux nephropathy, and VUR. Obstructive uropathy includes neurogenic bladder and obstructive uropathy. Hereditary disorders include Alport syndrome, cystinosis, familial hereditary disease, genetic nephrotic syndrome, metabolic disease–methylmalonic aciduria, nephronophthisis, oxalosis, polycystic kidney disease, and sickle cell nephropathy. Glomerulopathy includes focal segmental glomerulosclerosis, glomerulonephritis, Goodpasture syndrome, hemolytic uremic syndrome, Henoch–Schönlein purpura, IgA nephropathy, membranous nephropathy, and systemic lupus erythematosus.

Abbreviations: GFR, Glomerular filtration rate; CAKUT, congenital anomalies of the kidney and urinary tract; hypo/dys, hypoplastic dysplastic kidney; VUR, vesicoureteral reflux; KNOW-Ped CKD, KoreaN Cohort Study for Outcomes In Patients with Pediatric CKD; P-CKD, Pediatric CKD; TAPRC, Taiwan Pediatric Renal Collaborative; REPIR II, Spanish Paediatric Registry of Renal Failure; SPRECKID, Serbian Pediatric Registry of Chronic Kidney Disease; ItalKid, Italian Pediatric Registry of Chronic Renal Insufficiency; NAPRTCS, North American Pediatric Renal Trials and Collaborative Study; ; CKiD, Chronic Kidney Disease in Children.

dysplasia is present alongside hypoplasia. There are different degrees of renal hypoplasia, and it is obviously hard to say with certainty if a particular piece of kidney tissue has or has ever had some degree of renal function [28].

Obstructive uropathy

A relatively common condition known as obstructive uropathy occurs when an anatomical or functional issue prevents normal urinary flow (Table 5). Calculi, ureteral strictures, and transitional cell epithelial neoplasms are intrinsic obstruction causes along the ureters. Vascular lesions like aortic or iliac artery aneurysms, retroperitoneal cancers like colon or metastatic bladder cancer, or inflammatory conditions like retroperitoneal fibrosis can cause extrinsic compression. The valves, which are merely mucosal folds that develop abnormally at the posterior urethra and can obstruct the flow of urine from the bladder, are an anatomical abnormality that develops during the embryologic development of the urinary tract [29].

Focal segmental glomerulosclerosis

About 20% of children with the nephrotic syndrome have focal segmental glomerulosclerosis, which is characterized by progressive glomerular scarring (Table 6). Glomerulosclerosis is both focal, affecting a small number of glomeruli, and segmental, affecting a portion of the glomerular globe, at the beginning of the disease. Focal segmental glomerulosclerosis is characterized by proteinuria, which is typically accompanied by peripheral edema, hypercholesterolemia, and hypoalbuminemia. The nephrotic syndrome in children is defined as proteinuria (>1 g of urine protein/m^2 of body-surface area/day), hypercholesterolemia (>200 mg of total cholesterol/dl), hypoalbuminemia (<2.5 g of albumin/dl), and edema [30].

Table 5: Causes of obstructive uropathy in children [29].

Congenital cause(s)		Acquired cause(s)	
Disorder(s) of Ureter	Magaureter; Ecopic ureterocele; Ectopic ureter; Ureterovesical junction obstruction; Uretropelvic junction obstruction	Extrinsic	Retrocaval ureter; Vascular abnormalities; Infection; Neuroblastoma; Traumatoc hemorrhage; Reproperitoneal abnormalities; Pregnancy; Pelvic inflammatory disease; Ovarian cyst; Reproductive tract abnormalities; Regional enteritis; Appendicitis; Gastrointestinal abnormalities
Disorder(s) of bladder	Agenesis; Hypoplasmia; Intravesical ureterocele; Trigonal cyst	Intrinsic (Intramural)	Neoplasm – rhabdomyosarcoma; Anatomic strictures; Anticholinergic drugs; Spinal cord trauma; Myelodysplasia; Funcitonal
Disorder(s) of urethra	Urethral atresia; Congenital megalourethra; Severe meatal stenosis; Urethral diverticulate; Anterior urethral valves; Posterior urethral valves	Intrinsic (Intraluminal)	Fungus balls; Papillary necrosis; Nephrolithiasis; Bence-Jones Protein; Drugs - Sulfa, Methotrexate, Acyclovir; Uricosuria - leukemia, chemotherapy; Tubular deposition - protein, crystals

Table 6: Causes of focal segmental glomerulosclerosis [30].

Primary form	Idiopathic	Meidated by circulating permeability factors; Exact cause unknown
Secondary form	Adaptive	Reduced renal mass; Very low birth weight; Renal dysplasia; Systemic hypertension; Cyanotic congenital heart disease; Sickle cell anemia; Increased body-mass index
	Drug-induced	Anabolic steroids; Calcineurin-inhibitor nephrotoxicity; Sirolunys; Pamidronate; Lithium; Gamma, beta, and alpha interferons
	Virus-associated	Epstein-barr virus; Cytomegalovirus; Simian virus 40; Parvovirus B19; Human immunodeficiency virus type 1
	Genetic or familial	Specific podocyte genes mutations

Reflux nephropathy

The RN is currently categorized as either congenital (also known as primary), which is caused by abnormal renal development that results in focal renal dysplasia, or acquired, which is caused by pyelonephritis-induced renal injury (Table 7). Acquired reflux nephropathy (after urinary tract infection) or follow-up for antenatally diagnosed hydronephrosis with congenital reflux nephropathy (no prior urinary tract infection) is the most common diagnosis for "Reflux Nephropathy" in children. The congenital reflux nephropathy is more prevalent in male children, while the acquired reflux nephropathy is more prevalent in female children. In order to maintain renal function, reflux nephropathy must be diagnosed and treated promptly [31].

Table 7: Reflux nephropathy (congenital vs acquired) in children [31].

Histological/ Clinical feature(s)	Congenital	Acquired
Dysplastic characteristics on renal histopathology	Yes	No
Grade of vesicoureteral reflux	Predominently high grade	Any grade
Gender distribution	Mostly males	Mostly females
Age distribution	Predominently younder children	All pediatic age-range
Urinary tract infection diagnosis	Not common	Common
Time of occurrence	Prenatal	Postnatal

Polycystic disease

The ESRD is frequently brought on by cystic kidneys, and it affects both adults and children. The two most common forms of monogenic cystic kidney diseases are autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD), both of which are related to the cilia. While ARPKD is a rarer and frequently more severe form of polycystic kidney disease (PKD), it typically presents during pregnancy or early childhood, patients frequently die during pregnancy or infancy. ADPKD is a common disease that mostly affects adults. Mutations in polycystic kidney and hepatic disease 1 (PKHD1), which encodes the protein fibrocystin (also known as polyductin), which is found in the primary cilium and basal body, are the primary cause of ARPKD. Hepatic fibrosis and severely enlarged kidneys are disease manifestations, and cysts typically affect the collecting ducts. The polycystic kidneys and congenital hepatic fibrosis (CHF) seen in ARPKD suggest that the disease causes a disorder in the terminal differentiation of the renal collecting ducts and intrahepatic biliary ducts. Histological examination has shown that biliary duct ectasia, also known as ductal plate malformation, and defective remodelling of the ductal plate with CHF are the liver changes that are always present in patients with ARPKD from early embryonic development. The majority of cases of ARPKD are caused by various variants in PKHD1 (6p12.3 - 12.2), including missense and truncating mutations [32].

Chronic glomerulonephritis

Not only is glomerulonephritis the leading cause of childhood acquired chronic renal failure, but it may also cause ESRD or other complications that do not become apparent until adulthood. Proteinuria and asymptomatic hematuria or nephrotic syndrome and acute nephritic syndrome may accompany chronic glomerulonephritides that result in permanent loss of nephron mass. Common childhood glomerulonephritides that can lead to chronic renal failure include IgA nephropathy, Henoch-Schonlein purpura (HSP), and Membranoproliferative glomerulonephritis (MPGN). In the absence of treatment, MPGN results in chronic renal failure in ~90% of cases, whereas HSP-associated nephritis results in chronic renal failure in <1% to 2% of unselected cases. Although the long-term prognosis of IgA nephropathy is unknown, it is estimated that 20 to 40% of children with IgA nephropathy will eventually develop renal insufficiency [33].

Medullary cystic disease

A renal cystic disease known as medullary cystic kidney disease (MCKD) features the distinctive renal histologic triad of tubular basement membrane disintegration, tubular atrophy with the development of cysts, and interstitial cell infiltration with fibrosis [34]. It is an autosomal dominant condition. MCKD is now more accurately referred to as autosomal dominant tubulointerstitial kidney disease, which is a group of disorders characterized by autosomal dominant inheritance, bland urine with little protein and blood, pathologic changes in tubular and interstitial fibrosis, and chronic kidney disease that progresses slowly. Heterozygous mutations in the MUC1 gene are the root cause of MCKD of type 1 (MIM 174000) [35]. MCKD can be associated with lithiasis, acidosis, and tubular defects [36].

Hemolytic uremic syndrome

In otherwise healthy young children, acute renal failure with a fulminant, life-threatening systemic disease is uncommon; However, when it does occur, hemolytic uremic syndrome (HUS) is the most common cause. A few genetic mutations that cause uncontrolled activation of the complement system account for about 5% of childhood HUS cases. There are generally two main types of HUS: typical (D+HUS) and atypical (aHUS) or diarrhea-negative HUS. About 90% of HUS cases in children are linked to prodromal diarrhea caused by Shiga toxin-producing *Escherichia coli* infections that can attach to the intestinal wall; Enterohemorrhagic *E. coli* (EHEC) are these. *Streptococcus pneumoniae*-causes rare form of HUS, which usually occurs after invasive pulmonary infection. It is sometimes categorized as D+HUS in the infectious HUS group or in the aHUS group because it does not start with diarrhea. HUS is a rare disease with an annual incidence of 0.7 - 8 cases per 100,000 people and significantly varies with seasons and geography. At the moment, no specific treatment methods have been shown to affect D+HUS outcomes [37].

Prune belly

A congenital disorder known as prune-belly syndrome (PBS) is characterized by bilateral cryptorchidism, urinary tract anomalies, and a lack

of abdominal wall muscle. Defects in the gastrointestinal, pulmonary, skeletal, and cardiac systems are frequently linked to the syndrome. A major prognostic factor is urinary tract disease; complications like pulmonary hypoplasia and ESRD account for 60% of deaths. Hydronephrosis, dilated ureters, and megacystis are among the urinary tract abnormalities associated with PBS. Impairment in urination, renal hypoperfusion injury, pyelonephritis, recurrent urinary tract infections, and vesicoureteral reflux and stasis are all caused by these anomalies. Oligohydramnios and related deformities, such as pulmonary hypoplasia and skeletal deformities, are the consequences of in utero renal dysplasia. Severe renal dysplasia and pulmonary hypoplasia patients frequently succumb to respiratory failure during perinatal period. About 30% of newborn survivors will develop chronic renal insufficiency or ESRD by childhood or adolescence, necessitating dialysis or transplantation [38].

Congenital nephrotic syndrome

Within the first three months of life, children with congenital nephrotic syndrome (CNS) present symptoms. Mutations in genes that code for glomerular filtration barrier components typically result in primary CNS. The Finnish type of CNS (CNF, NPHS1) is the classic form. It is caused by mutations in the NPHS1 (nephrin) gene, and in newborns, it typically results in severe proteinuria. CNS can also be caused by pathogenic variants in other genes like PLCE1 (phospholipase C epsilon 1, NPHS3), LAMB2 (laminin β2), WT1 (Wilms tumor suppressor 1), and NPHS2 (podocin). These genes all have more variable clinical manifestations, including a wider age range at the onset of the disease. Together, mutations in these five genes account for more than 80% of CNS patients. Other diseases, such as congenital infections or immune disorders, can also have a secondary effect on the CNS. The clinical presentation, family history, laboratory results, genetic testing, and histology all play a role in making a CNS diagnosis and the underlying etiology. For most patients with genetic CNS, kidney transplantation is the only curative treatment, although certain forms of secondary CNS can be managed medically. After reaching a body weight of 7–10 kg, bilateral nephrectomy, dialysis, and transplantation may be considered for unstable patients with refractory nephrotic states. Nephrectomy is not necessary in stable patients, and when they reach ESRD, renal replacement therapy is started. When the patient is no longer nephrotic, transplantation should be performed [39].

Familial nephritis

Alport syndrome and thin basement membrane nephropathy are typically used to describe hereditary/familial nephritis. About 6% of children suffer from nonglomerular, transient hematuria, typically caused by cystitis or familial hypercalciuria [40]. Alport syndrome is a disease which can be hereditary in families, and about 80% of patients have a positive family history that suggests other family members were involved [41].

Cystinosis

The most common genetic cause of renal Fanconi syndrome in children is cystinosis. Mutations in the CTNS gene that encode for the carrier protein cystinosin, which transports cystine out of the lysosomal compartment, cause this autosomal recessive lysosomal storage disorder. All body cells and organs accumulate cystine intra-lysosomally when cystinosin function is compromised. In the first year of life, proximal tubular damage affects the kidneys. If treatment is not received, this is followed by progressive glomerular damage and end-stage renal failure in the middle of childhood. The cystine depleting agent cysteamine, renal replacement therapy, hormonal therapy, and other treatments are available for cystinosis. However, there is no cure at this time [42].

Epidemiology

Although the global incidence of ESRD in children has been steady over the last 30 years, the frequency is rising, as is the incidence among dialysis and renal transplant patients [43, 44]. In 2008, the global median incidence of RRT in children under the age of 20 was roughly 9 per million age-matched population (pmarp), and it was much higher in the United States, with a median of 15.5 pmarp [45]. Race has a regional impact, with black children in the United States having double the frequency of ESRD as white children. Adolescents have a greater prevalence of RRT than any other age group worldwide, with the United States much higher than Western Europe in both the 0-1 and 15-19 age groups. is superior to the etiology of CKD varies by age and race, with black adolescents more likely to develop the glomerular-based illness with the focal segmental nephrotic syndrome than white adolescents. Children under the age of 12 are more prone to develop CAKUT (Congenital anomalies of the kidney and urinary tract). is greater. Recent investigations have indicated early renal impairment in young children and their risk of CKD. Childhood obesity is a growing concern across the world [46, 47]. Additionally, teenagers with low birth weight or small-for-gestational-age infants are more likely to have an advanced illness. Mass screening programs for chronic illnesses in children have been created in several Asian nations, including Japan, Taiwan, and Korea. While urine screening swabs have been regularly used in healthy children in the United States for decades, screening programs have not been adopted in Europe. Although there has been a decline in the prevalence of ESRD in Japan and Taiwan, there is no evidence that early identification of kidney impairment in children can result in efficient therapies that further lower the risk of acquiring ESRD and delay the course of CKD [48].

Complications of CKD

CKD is defined as renal damage represented as aberrant albumin secretion or reduced renal function, measured or assessed as GFR, lasting more than three months. Children and adults with CKD are affected by quite distinct reasons. Since 1999, the NAPRTCS registry in the United States has been compiling information on childhood chronic illness in its early phases [49]. In 14% of instances, glomerulonephritis was detected. By age, the distribution of causes varied. While glomerulonephritis was the primary cause in children older than 12 years old, CAKUT predominated in patients who were younger. The major cause of glomerular disease, focal segmental glomerulosclerosis, is three times more prevalent in blacks than in whites (19 vs 6%), particularly in young blacks (35%). Stage 1 chronic illnesses are present in 1.8% of the United States population, stage 2 in 3.2%, stage 3 in 7.7%, and stage 5 in 0.35% of the population. At a rate of 1.5% each year, patients with stage 3 or illness develop to end-stage or stage 5. At a rate of around 0.5% each year, patients with stage 1 or stage 2 CKD move to advanced stage 5.

Unique Problems in Pediatrics

Genetic disorders

The possibilities for diagnosing genetic abnormalities have increased because of the recent decoding and sequencing of the human genome. Prior to the data becoming accessible for prospective therapeutic applications, it is currently challenging for scientists and researchers to determine the advantages and disadvantages of genomics in comparison to exome sequencing to uncover the genetic origins of primary immunodeficiencies [50]. Evidence from epidemiological, clinical, cellular, and molecular studies suggests that the environment in which a fetus develops has a significant impact on its programming. Telomere biology may be a shared underlying mechanism connecting prenatal programming and subsequent health or vulnerability to complicated illnesses [51]. Studying the biological processes of fetal programming is drawing interest and study.

Bladder dysfunction and transplantation

The pediatric ESRD population has difficulties in the lead-up to transplantation since it is the most frequent cause of birth abnormalities. A high-pressure-low-pressure bubble can be transformed into a low-pressure bubble with improved compliance using the technique known as bubble augmentation. In addition to the risks that may occur if the intestinal segment affects a specific location and carcinogenesis associated with expansion cystoplasty itself, kidney transplantation in the presence of an expanded bladder has certain severe graft loss. Graft regurgitation, ureteral blockage, bladder dysfunction, urinary tract infection, mucus buildup in a section of the intestine leading to the closure of the outlet or Foley catheter, especially in the first few days after transplant, and fistula development are some of these issues [52]. The danger of doing the same kind of harm to the transplanted kidney as to the original kidney is the main worry when transplanting into a failing bladder without augmentation. Consequently, a lot of people advise augmentation before transplantation [53].

Teenage medication compliance and transition to adult services

Pediatric transplants had the greatest medication failure rate among young persons [54], and graft failure begins to rise at age 11 and peaks between age 17 and 2 years [55]. It is a challenging developmental stage marked by physical maturation prior to emotional maturity and frequently accompanied by deficiencies in motivation and decision-making, organizational abilities, risk perception, and logical thinking that gradually worsen [56]. When health education, parental participation, self-monitoring, reinforcement, and problem-solving are included in intervention efforts to increase adherence, they are often beneficial [57]. Before transferring to adult care, Bell and Sawyer [58] advise patients to pass a number of crucial milestones, such as being able to explain the cause of their sickness, the necessity for a transplant, and exhibiting self-care. Once a transition has taken place, it is crucial that pediatric and adult healthcare professionals stay in touch so that adult healthcare professionals are aware of the specific difficulties linked to CAKUT anomalies and developmental changes in young people.

An Instrument for Measuring Health-Related Quality of Life

We utilized the "Pediatric QOL Inventory 4.0" measure, which assesses the HRQL of healthy children and adolescents as well as those with acute illnesses and chronic conditions, to create the meta-analysis. It is a generic instrument with 23 items on a Likert-type answer scale (0 = never to 4 virtually usually), and it measures four different aspects of functioning: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and functioning in the classroom (5 items). The scale comes in four variations depending on the child's age: two years (for preschoolers), seven to twelve years (for kids), and thirteen to eighteen years (for teenagers).

Conclusion

Children with CKD have dynamic, complicated, medical, and psychosocial conditions with characteristics that set them apart from adults. The scientific community in pediatric nephrology has done excellent and fascinating work concentrating on this demographic, and evidence-based care of this population is expanding. The effect of CKD on a pediatric population's health-related QOL was discovered using meta-analysis. Due to frequent doctor visits and sickness symptoms, school was the dimension most negatively impacted; juvenile patients' physical performance was also poor in this dimension. The key to achieving these research objectives will be multicenter collaborations and partnerships like those that have already been developed and exemplified by the Midwest Pediatric Nephrology Consortium, the CKiD cohort, and the NAPRTCS.

References

1. Ribeiro KRA 2016. Cuidados de enfermagem aos pacientes com insuficiência renal crônica no ambiente hospitalar. *Revista Recien-Revista Científica de Enfermagem* 6: 26-35. https://doi.org/10.24276/rrecien2358-3088.2016.6.18.26-35

2. Jesus NM, Souza GFD, Mendes-Rodrigues C, Almeida OPD, Rodrigues DDM, et al. 2019. Quality of life of individuals with chronic kidney disease on dialysis. *J Bras Nefrol* 41: 364-374. https://doi.org/10.1590/2175-8239-JBN-2018-0152

3. Flores JC 2010. Chronic Kidney Disease: epidemiology and risk factors. *Rev Méd Clín Condes* 21: 502-507. https://doi.org/10.1016/S0716-8640(10)70565-4

4. Documento Marco sobre Enfermedad Renal Crónica (ERC) dentro de la Estrategia de Abordaje a la Cronicidad en el SNS. [https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/Enfermedad_Renal_Cronica_2015.pdf]

5. García de Vinuesa S 2008. Progression factors for chronic kidney disease. Secondary prevention. *Nefrologia* 28: 17-21.

6. Carrasco Hidalgo-Barquero M, de Cea Crespo JM 2014. Hematuria. *Protoc Diagn Ter Pediatr* 1: 53-68.

7. Eckardt KU, Berns JS, Rocco MV, Kasiske BL 2009. Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDOQI and KDIGO. *Am J Kidney Dis* 53: 915-920. https://doi.org/10.1053/j.ajkd.2009.04.001

8. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, et al. 2009. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol* 20: 629-637. https://doi.org/10.1681/ASN.2008030287

9. Rebollo P, Ortega F, Ortega T, Valdés C, García-Mendoza M, et al. 2003. Spanish validation of the" Kidney Transplant Questionnaire": a useful instrument for assessing health related quality of life in kidney transplant patients. *Health Qual Life Outcomes* 1: 56. https://doi.org/10.1186/1477-7525-1-56

10. Tomás Bernabeu E, Junqué Jiménez A, Iza Pinedo G, Luceño Solé I, Paz López O, et al. 2013. Beneficios de un programa de entrenamiento físico en la sintomatología depresiva y calidad de vida en los pacientes en hemodiálisis. *Enfermería Nefrológica* 16: 170-171. https://dx.doi.org/10.4321/S2254-28842013000500086

11. Amanullah F, Malik AA, Zaidi Z 2022. Chronic kidney disease causes and outcomes in children: perspective from a LMIC setting. *PLoS One* 17: e0269632. https://doi.org/10.1371/journal.pone.0269632

12. Kovesdy CP 2022. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl* 12: 7-11. https://doi.org/10.1016/j.kisu.2021.11.003

13. Baum M 2010. Overview of chronic kidney disease in children. *Curr Opin Pediatr* 22: 158-160. https://doi.org/10.1097/MOP.0b013e32833695cb

14. Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL 2012. CKiD (CKD in children) prospective cohort study: a review of current findings. *Am J Kidney Dis* 60: 1002-1011. https://doi.org/10.1053/j.ajkd.2012.07.018

15. Harambat J, Madden I 2022. What is the true burden of chronic kidney disease in children worldwide?. *Pediatr Nephrol* 1-5. https://doi.org/10.1007/s00467-022-05816-7

16. Ishikura K, Uemura O, Ito S, Wada N, Hattori M, et al. 2013. Pre-dialysis chronic kidney disease in children: results of a nationwide survey in Japan. *Nephrol Dial Transplant* 28: 2345-2355. https://doi.org/10.1093/ndt/gfs611

17. Kim JJ, Booth CJ, Waller S, Rasmussen P, Reid CJ, et al. 2013. The demographic characteristics of children with chronic kidney disease stages 3–5 in South East England over a 5-year period. *Arch Dis Child* 98: 189-194. https://doi.org/10.1136/archdischild-2012-302400

18. Al-Eisa A, Naseef M, Al-Hamad N, Pinto R, Al-Shimeri N, et al. 2005. Chronic renal failure in Kuwaiti children: an eight-year experience. *Pediatr Nephrol* 20: 1781-1785. https://doi.org/10.1007/s00467-005-2000-z

19. Landau D, Schreiber R, Kleinman A, Vodonos A, Shalev H 2013. Pediatric chronic kidney disease rates in Southern Israel are higher than reported. *F1000Res* 2: 186. https://doi.org/10.12688/f1000research.2-186.v1

20. Soylemezoglu O, Duzova A, Yalçınkaya F, Arınsoy T, Süleymanlar G 2012. Chronic renal disease in children aged 5–18 years: a population-based survey in Turkey, the CREDIT-C study. *Nephrol Dial Transplant* 27: iii146-iii151. https://doi.org/10.1093/ndt/gfs366

21. Gheissari A, Kelishadi R, Roomizadeh P, Abedini A, Haghjooy-Javanmard S, et al. 2013. Chronic kidney disease stages 3-5 in Iranian children: need for a school-based screening strategy: the CASPIAN-III study. *Int J Prev Med* 4: 95.

22. Song P, Wang M, Chang X, Wang J, Wei W, et al. 2019. Prevalence and associated factors of impaired renal function in C hinese children: the China Health and Nutrition Survey. *Nephrology* 24: 195-201. https://doi.org/10.1111/nep.13178

23. Harada R, Hamasaki Y, Okuda Y, Hamada R, Ishikura K 2022. Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies. *Pediatr Nephrol* 37: 1215-1229. https://doi.org/10.1007/s00467-021-05145-1

24. Sharma A, Ramanathan R, Posner M, Fisher RA 2013. Pediatric kidney transplantation: a review. *Transpl Res Risk Manag* 5: 21-31. https://doi.org/10.2147/TRRM.S34043

25. Davis ID, Greenbaum LA, Gipson D, Wu LL. Sinha R, et al. 2012. Prevalence of sleep disturbances in children and adolescents with chronic kidney disease. *Pediatr Nephrol* 27: 451-459. https://doi.org/10.1007/s00467-011-2010-y

26. Hiraoka M, Tsukahara H, Ohshima Y, Kasuga K, Ishihara Y, Mayumi M 2002. Renal aplasia is the predominant cause of congenital solitary kidneys. *Kidney Int* 61: 1840-1844. https://doi.org/10.1046/j.1523-1755.2002.00322.x

27. Glassberg KI 2002. Normal and abnormal development of the kidney: a clinician's interpretation of current knowledge. *J Urology* 167: 2339-2350. https://doi.org/10.1016/S0022-5347(05)64982-8

28. Nation EF 1944. Renal aplasia: a study of sixteen cases. *J Urology* 51: 579-586. https://doi.org/10.1016/S0022-5347(17)70396-5

29. Tseng TY, Stoller ML 2009. Obstructive uropathy. *Clin Geriatr Med* 25: 437-443. https://doi.org/10.1016/j.cger.2009.06.003

30. D'Agati VD, Kaskel FJ, Falk RJ 2011. Focal segmental glomerulosclerosis. *N Eng J Med* 365: 2398-2411. https://doi.org/10.1056/NEJMra1106556

31. Mattoo TK 2011. Vesicoureteral reflux and reflux nephropathy. *Adv Chronic Kidney Dis* 18: 348-354. https://doi.org/10.1053/j.ackd.2011.07.006

32. Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJ, Torres VE 2018. Polycystic kidney disease. *Nat Rev Dis Primers* 4: 50. https://doi.org/10.1038/s41572-018-0047-y

33. Andreoli SP 1995. Chronic glomerulonephritis in childhood: membranoproliferative glomerulonephritis, Henoch-Schönlein purpura nephritis, and IgA nephropathy. *Pediatr Clin North Am* 42: 1487-1503. https://doi.org/10.1016/S0031-3955(16)40095-7

34. Hildebrandt F, Omram H 2001. New insights: nephronophthisis-medullary cystic kidney disease. *Pediatr Nephrol* 16: 168-176. https://doi.org/10.1007/s004670000518

35. Cramer MT, Guay-Woodford LM 2015. Cystic kidney disease: a primer. Adv Chronic *Kidney Dis* 22: 297-305. https://doi.org/10.1053/j.ackd.2015.04.001

36. Meola M, Samoni S, Petrucci I 2016. Clinical scenarios in chronic kidney disease: cystic renal diseases. *Contrib Nephrol* 188: 120-130. https://doi.org/10.1159/000445474

37. Grisaru S 2014. Management of hemolytic-uremic syndrome in children. *Int J Nephrol Renovasc Dis* 7: 231-239. https://doi.org/10.2147/IJNRD.S41837

38. Bogart MM, Arnold HE, Greer KE 2006. Prune-belly syndrome in two children and review of the literature. *Pediatr Dermatol* 23: 342-345. https://doi.org/10.1111/j.1525-1470.2006.00265.x

39. Jalanko H, Jahnukainen T, Ng KH 2022. Congenital nephrotic syndrome. In Emma F, Goldstein SL, Bagga A, Bates CM, Shroff R (eds) Pediatric nephrology. Springer Cham.

40. Savige J 2022. Hereditary nephritis in children. In Craig JC, Molony DA, Strippoli GFM (eds) Evidence-based nephrology. John Wiley & Sons Ltd.

41. Madani A, Fahimi D, Esfehani ST, Mohsseni P, Atayee N, et al. 2003. Glomerular diseases in Iranian children: clinico-pathological correlations. *Pediatr Nephrol* 18: 925-928. https://doi.org/10.1007/s00467-003-1166-5

42. Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, et al. 2016. Cystinosis: a review. *Orphanet J Rare Dis* 11: 47. https://doi.org/10.1186/s13023-016-0426-y

43. Harambat J, van Stralen KJ, Kim JJ, Tizard EJ 2012. Epidemiology of chronic kidney disease in children. *Pediatr Nephrol* 27: 363-373. https://doi.org/10.1007/s00467-011-1939-1

44. Xiao N, Jenkins TM, Nehus E, Inge TH, Michalsky MP, et al. 2014. Kidney function in severely obese adolescents undergoing bariatric surgery. *Obesity* 22: 2319-2325. https://doi.org/10.1002/oby.20870

45. Ding W, Cheung WW, Mak RH 2015. Impact of obesity on kidney function and blood pressure in children. *World J Nephrol* 4: 223-229. https://doi.org/10.5527/wjn.v4.i2.223

46. Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM 2008. Low birth weight increases risk for end-stage renal disease. *J Am Soc Nephrol* 19: 151-157. https://doi.org/10.1681/ASN.2007020252

47. Carmody JB, Charlton JR 2013. Short-term gestation, long-term risk: prematurity and chronic kidney disease. *Pediatrics* 131: 1168-1179. https://doi.org/10.1542/peds.2013-0009

48. Murakami M, Hayakawa M, Yanagihara T, Hukunaga Y 2005. Proteinuria screening for children. *Kidney Int* 67: S23-S27. https://doi.org/10.1111/j.1523-1755.2005.09406.x

49. Lin CY, Sheng CC, Chen CH, Lin CC, Chou P 2000. The prevalence of heavy proteinuria and progression risk factors in children undergoing urinary screening. *Pediatr Nephrol* 14: 953-959. https://doi.org/10.1007/s004679900278

50. Cho BS, Kim SD 2007. School urinalysis screening in Korea. *Nephrology* 12: S3-S7. https://doi.org/10.1111/j.1440-1797.2007.00873.x

51. Hogg RJ 2009. Screening for CKD in children: a global controversy. *Clin J Am Soc Nephrol* 4: 509-515. https://doi.org/10.2215/CJN.01210308

52. Kidney Disease Outcomes Quality Initiative 2007. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. *Am J Kidney Dis* 50: 471-530. https://doi.org/10.1053/j.ajkd.2007.06.008

53. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, et al. 2005. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 67: 2089-2100. https://doi.org/10.1111/j.1523-1755.2005.00365.x

54. Fivush BA, Jabs K, Neu AM, Kenneth Sullivan E, Feld L, et al. 1998. Chronic renal insufficiency in children and adolescents: the 1996 annual report of NAPRTCS. *Pediatr Nephrol* 12: 328-337. https://doi.org/10.1007/s004670050462

55. Hsu CY, Vittinghoff E, Lin F, Shlipak MG 2004. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. *Ann Intern Med* 141: 95-101. https://doi.org/10.7326/0003-4819-141-2-200407200-00007

56. Chou J, Ohsumi TK, Geha RS 2012. Use of whole exome and genome sequencing in the identification of genetic causes of primary immunodeficiencies. *Curr Opin Allergy Clin Immunol* 12: 623-628. https://doi.org/10.1097/ACI.0b013e3283588ca6

57. Entringer S, Buss C, Wadhwa PD 2012. Prenatal stress, telomere biology, and fetal programming of health and disease risk. *Sci Signal* 5: 12. https://doi.org/10.1126/scisignal.2003580

58. Jesus LE, Salle JP 2015. Pre-transplant management of valve bladder: a critical literature review. *J Pediatr Urol* 11: 5-11. https://doi.org/10.1016/j.jpurol.2014.12.001